» Articles » PMID: 15315511

Pregabalin Pharmacology and Its Relevance to Clinical Practice

Overview
Journal Epilepsia
Specialty Neurology
Date 2004 Aug 19
PMID 15315511
Citations 145
Authors
Affiliations
Soon will be listed here.
Abstract

Pregabalin is a potent ligand for the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system that exhibits potent anticonvulsant, analgesic, and anxiolytic activity in a range of animal models. In addition, pregabalin has been shown to be a highly effective adjunctive therapy for partial seizures in clinical trials. Potent binding to the alpha-2-delta site reduces depolarization-induced calcium influx with a consequential modulation in excitatory neurotransmitter release. Pregabalin has no demonstrated effects on GABAergic mechanisms. Pregabalin demonstrates highly predictable and linear pharmacokinetics, a profile that makes it easy to use in clinical practice. Absorption is extensive, rapid, and proportional to dose. Time to maximal plasma concentration is approximately 1 h and steady state is achieved within 24-48 h. These characteristics reflect the observed onset of efficacy as early as day two in clinical trials. High bioavailability, a mean elimination half life (t(1/2)) of 6.3 h, and dose-proportional maximal plasma concentrations and total exposures predict a dose-response relationship in clinical practice and allow an effective starting dose of 150 mg/day in clinical practice without need for titration. Administration with food has no clinically relevant effect on the amount of pregabalin absorbed, providing for a dosing regimen uncomplicated by meals. Pregabalin does not bind to plasma proteins and is excreted virtually unchanged (<2% metabolism) by the kidneys. It is not subject to hepatic metabolism and does not induce or inhibit liver enzymes such as the cytochrome P450 system. Therefore, pregabalin is unlikely to cause, or be subject to, pharmacokinetic drug-drug interactions--an expectation that has been confirmed in clinical pharmacokinetic studies. However, dose adjustment may be necessary in patients with renal insufficiency. Thus, the pharmacological and pharmacokinetic profiles of pregabalin provide a predictable basis for its use in clinical practice.

Citing Articles

Impact of Genetic Variants on Pregabalin Pharmacokinetics and Safety.

Calleja S, Rodriguez-Lopez A, Ochoa D, Luquero S, Navares-Gomez M, Roman M Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40005966 PMC: 11860030. DOI: 10.3390/ph18020151.


Investigating the Relationship Between Anti-seizure Medications and Bleeding Disorders: A Comprehensive Review of the Current Literature.

Mansoor A, Shahzad M, Zulfiqar E, Ahsan M, Adnan R, Shaeen S Drugs Real World Outcomes. 2025; 12(1):1-15.

PMID: 39752064 PMC: 11829880. DOI: 10.1007/s40801-024-00462-x.


Prescribing Patterns of Gabapentinoids in Chronic Pain Management: A Single Institution Retrospective Chart Review.

Tran R, Patil A, Nguyen P, Nguyen G, Qadeer A, Chen G Psychopharmacol Bull. 2025; 55(1):26-36.

PMID: 39744414 PMC: 11626918.


Efficacy of gabapentin and pregabalin for treatment of post refractive surgery pain: a systematic review and meta-analysis.

Chen K, Chan H, Wei L, Chan C Int Ophthalmol. 2024; 44(1):409.

PMID: 39448432 DOI: 10.1007/s10792-024-03300-9.


Role of Pregabalin in Pre-Operative and Post-Operative Pain Management of Lower Limb Orthopedic Surgeries.

Adharsh K, Arun S, Pradeep E, Kumar K, Pandian H, Sheik M J Orthop Case Rep. 2024; 14(10):263-269.

PMID: 39381296 PMC: 11458241. DOI: 10.13107/jocr.2024.v14.i10.4884.